Winston-Salem, North Carolina. Javara Inc., today announced the launch of its Integrated Research Organization (IRO) platform to drive innovative research partnerships, service, and technology offerings to healthcare systems, including
Accountable Care Organizations, Academic and Community-Based systems. Together, Javara and its healthcare partners will offer a more aligned, efficient, and effective solution to the challenges of patient inclusion in clinical trials, by creating an infrastructure where clinical research will become an integral part of the state-of-the-art healthcare delivery offered by Javara’s healthcare partners.
“Today, biopharmaceutical companies are developing truly innovative therapies for patients. Yet, patients, who simply cannot wait, continue to face incredible challenges in accessing clinical trials and frustration in the slow completion of clinical trials,” said Jeff Kasher, Ph.D, Pharmaceutical Development Executive and Javara Board Director. “By focusing on the healthcare ecosystem, Javara aims to make clinical research more efficient, relevant, and more accessible.”
Jennifer Byrne, co-founder and CEO of Javara is a long time clinical research leader with a proven track record. Under her leadership, Javara has assembled a top-flight talent team and a blue-chip Board of Directors (www.javararesearch.com), all deeply committed to advancing the relevance and efficiency of clinical research to the healthcare ecosystem. The Javara IRO platform will bring better outcomes for patient-centered care, better economic results and easier access to cutting edge therapies for healthcare systems, and a more valuable and reliable research delivery model to the biopharmaceutical sector. Ms. Byrne commented, “Strong market forces are driving the need for transformational and innovative partnerships for both healthcare organizations and drug and device developers, all while delivering a higher quality and higher touch clinical trial experience to patients. Historically, healthcare and drug development sectors have largely operated in silos. Javara’s mission is to build extraordinary bridges between healthcare and the research industry to effectively and efficiently accelerate drug development.”
Jennifer Byrne
CEO Javara
jbyrne@javararesearch.com
(336) 414-0814
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.